The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo

M Chen; S Brøgger Christensen; L Zhai; M H Rasmussen; T G Theander; S Frøkjaer; B Steffansen; J Davidsen; A Kharazmi

The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo

M Chen, S Brøgger Christensen, L Zhai, M H Rasmussen, T G Theander, S Frøkjaer, B Steffansen, J Davidsen, A Kharazmi

121 Citations (Scopus)

Abstract

Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was designed to examine the antimalarial activity of an analog of licochalcone A, 2,4-dimethoxy-4'-butoxychalcone (2,4mbc). 2,4mbc inhibited the in vitro growth of both a chloroquine-susceptible (3D7) and a chloroquine-resistant (Dd2) strain of Plasmodium falciparum in a [3H]hypoxanthine uptake assay. The in vivo activity of 2,4mbc was tested in mice infected with Plasmodium berghei or Plasmodium yoelii and in rats infected with P. berghei. 2,4mbc administered either orally, intraperitoneally, or subcutaneously for 5 days protected the mice from otherwise lethal infections of these parasites. 2,4mbc administered orally for 5 days reduced parasitemia in the rats infected with P. berghei. These results demonstrate that 2,4mbc exhibits potent antimalarial activity and might be developed into a new antimalarial drug.

Original language	English
Journal	Journal of Infectious Diseases
Volume	176
Issue number	5
Pages (from-to)	1327-33
Number of pages	6
ISSN	0022-1899
Publication status	Published - 1997

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Fingerprint

Dive into the research topics of 'The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo'. Together they form a unique fingerprint.

Cite this

Chen, M., Brøgger Christensen, S., Zhai, L., Rasmussen, M. H., Theander, T. G., Frøkjaer, S., Steffansen, B., Davidsen, J., & Kharazmi, A. (1997). The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. Journal of Infectious Diseases, 176(5), 1327-33.

The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. / Chen, M; Brøgger Christensen, S; Zhai, L et al.
In: Journal of Infectious Diseases, Vol. 176, No. 5, 1997, p. 1327-33.

Research output: Contribution to journal › Journal article › Research › peer-review

Chen, M, Brøgger Christensen, S, Zhai, L, Rasmussen, MH, Theander, TG , Frøkjaer, S, Steffansen, B, Davidsen, J & Kharazmi, A 1997, 'The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo', Journal of Infectious Diseases, vol. 176, no. 5, pp. 1327-33.

@article{f0e236c0a0d811dd86a6000ea68e967b,

title = "The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo",

abstract = "Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was designed to examine the antimalarial activity of an analog of licochalcone A, 2,4-dimethoxy-4'-butoxychalcone (2,4mbc). 2,4mbc inhibited the in vitro growth of both a chloroquine-susceptible (3D7) and a chloroquine-resistant (Dd2) strain of Plasmodium falciparum in a [3H]hypoxanthine uptake assay. The in vivo activity of 2,4mbc was tested in mice infected with Plasmodium berghei or Plasmodium yoelii and in rats infected with P. berghei. 2,4mbc administered either orally, intraperitoneally, or subcutaneously for 5 days protected the mice from otherwise lethal infections of these parasites. 2,4mbc administered orally for 5 days reduced parasitemia in the rats infected with P. berghei. These results demonstrate that 2,4mbc exhibits potent antimalarial activity and might be developed into a new antimalarial drug.",

author = "M Chen and {Br{\o}gger Christensen}, S and L Zhai and Rasmussen, {M H} and Theander, {T G} and S Fr{\o}kjaer and B Steffansen and J Davidsen and A Kharazmi",

note = "Keywords: Animals; Antimalarials; Chalcone; Chalcones; Drug Resistance; Female; Humans; Malaria; Male; Mice; Mice, Inbred BALB C; Monocytes; Neutrophils; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Rats; Rats, Wistar",

year = "1997",

language = "English",

volume = "176",

pages = "1327--33",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo

AU - Chen, M

AU - Brøgger Christensen, S

AU - Zhai, L

AU - Rasmussen, M H

AU - Theander, T G

AU - Frøkjaer, S

AU - Steffansen, B

AU - Davidsen, J

AU - Kharazmi, A

N1 - Keywords: Animals; Antimalarials; Chalcone; Chalcones; Drug Resistance; Female; Humans; Malaria; Male; Mice; Mice, Inbred BALB C; Monocytes; Neutrophils; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Rats; Rats, Wistar

PY - 1997

Y1 - 1997

N2 - Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was designed to examine the antimalarial activity of an analog of licochalcone A, 2,4-dimethoxy-4'-butoxychalcone (2,4mbc). 2,4mbc inhibited the in vitro growth of both a chloroquine-susceptible (3D7) and a chloroquine-resistant (Dd2) strain of Plasmodium falciparum in a [3H]hypoxanthine uptake assay. The in vivo activity of 2,4mbc was tested in mice infected with Plasmodium berghei or Plasmodium yoelii and in rats infected with P. berghei. 2,4mbc administered either orally, intraperitoneally, or subcutaneously for 5 days protected the mice from otherwise lethal infections of these parasites. 2,4mbc administered orally for 5 days reduced parasitemia in the rats infected with P. berghei. These results demonstrate that 2,4mbc exhibits potent antimalarial activity and might be developed into a new antimalarial drug.

AB - Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was designed to examine the antimalarial activity of an analog of licochalcone A, 2,4-dimethoxy-4'-butoxychalcone (2,4mbc). 2,4mbc inhibited the in vitro growth of both a chloroquine-susceptible (3D7) and a chloroquine-resistant (Dd2) strain of Plasmodium falciparum in a [3H]hypoxanthine uptake assay. The in vivo activity of 2,4mbc was tested in mice infected with Plasmodium berghei or Plasmodium yoelii and in rats infected with P. berghei. 2,4mbc administered either orally, intraperitoneally, or subcutaneously for 5 days protected the mice from otherwise lethal infections of these parasites. 2,4mbc administered orally for 5 days reduced parasitemia in the rats infected with P. berghei. These results demonstrate that 2,4mbc exhibits potent antimalarial activity and might be developed into a new antimalarial drug.

M3 - Journal article

C2 - 9359735

SN - 0022-1899

VL - 176

SP - 1327

EP - 1333

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -